Committee Print

[SHOWING THE TEXT OF H.R. 1550, AS FAVORABLY FORWARDED BY THE
ENERGY AND COMMERCE SUBCOMMITTEE ON HEALTH ON JULY 15, 2021]

117TH CONGRESS
1ST SESSION

H. R. 1550

To amend the Public Health Service Act to provide for a public awareness
campaign with respect to human papillomavirus, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

MARCH 3, 2021

Ms. CASTOR of Florida (for herself and Ms. SCHRIER) introduced the
following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Public Health Service Act to provide for
a public awareness campaign with respect to human
papillomavirus, and for other purposes.

Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Promoting Resources
to Expand Vaccination, Education, and New Treatments
for HPV Cancers Act of 2021” or the “PREVENT HPV
Cancers Act of 2021”.

Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SEC. 2. PREVENTING HPV AND HPV-ASSOCIATED CANCERS; REAUTHORIZING JOHANNA’S LAW.

Section 317P of the Public Health Service Act (42 U.S.C. 247b–17) is amended—

(1) in subsection (c)(1)—

(A) in subparagraph (B), by striking “cervical” each time it appears;

(B) in subparagraph (C), by striking “and” at the end;

(C) in subparagraph (D) by striking “other” and all that follows through “cancer.” and inserting “recommended diagnostics for early intervention for, and prevention of, HPV-associated cancers; and”; and

(D) by adding at the end the following:

“(E) the importance of recommended vaccines for prevention of HPV and HPV-associated cancers, including for males;”; and

(2) by amending subsection (d) to read as follows:

“(d) JOHANNA’S LAW.—

“(1) NATIONAL PUBLIC AWARENESS CAMPAIGN.—

“(A) IN GENERAL.—The Secretary shall carry out a national campaign to increase the awareness and knowledge of health care pro-
viders and individuals with respect to
gynecologic cancers, HPV, and HPV-associated
cancers, and the importance of HPV vaccines in
preventing HPV and HPV-associated cancers.

“(B) WRITTEN MATERIALS.—Activities
under the national campaign under subpara-
graph (A) shall include—

“(i) maintaining a supply of written
materials that provide information to the
public on gynecologic cancers, HPV, and
HPV-associated cancers; and

“(ii) distributing the materials to
members of the public upon request.

“(C) PUBLIC SERVICE ANNOUNCE-
MENTS.—Activities under the national cam-
paign under subparagraph (A) shall, in accord-
ance with applicable law and regulations, in-
clude publishing materials in digital or print
form, public engagement, and developing and
placing public service announcements intended
to encourage individuals to discuss with their
physicians—

“(i) their risk of gynecologic cancers
and HPV-associated cancers; and
“(ii) the importance of HPV vaccines in preventing HPV and HPV-associated cancers.

“(D) TARGETED POPULATIONS.—Activities under the national campaign under subparagraph (A) shall include culturally and linguistically competent public service announcements and other forms of communication and public engagement under subparagraph (C) targeted to—

“(i) specific higher-risk populations of individuals based on race, ethnicity, level of acculturation, and family history, including African-American and Ashkenazi Jewish individuals;

“(ii) communities with high rates of unvaccinated individuals, including males;

“(iii) rural communities;

“(iv) populations affected by increasing rates of oropharynx cancers; and

“(v) such other communities as the Secretary determines appropriate.

“(2) CONSULTATION.—In carrying out the national campaign under this section, the Secretary shall consult with—
“(A) health care providers;

“(B) nonprofit organizations (including gynecologic cancer organizations and organizations that represent communities and individuals most affected by HPV-associated cancers and low vaccination rates);

“(C) State and local public health departments; and

“(D) elementary and secondary education organizations and institutions of higher education.

“(3) DEMONSTRATION PROJECTS REGARDING OUTREACH AND EDUCATION STRATEGIES.—

“(A) IN GENERAL.—

“(i) PROGRAM.—The Secretary may carry out a program to award grants or contracts to public or nonprofit private entities for the purpose of carrying out demonstration projects to test, compare, and evaluate different evidence-based outreach and education strategies to increase the awareness and knowledge of women, their families, physicians, nurses, and other key health professionals with respect to gynecologic cancers, including with respect
to early warning signs, risk factors, prevention, screening, and treatment options.

“(ii) SCIENCE-BASED RESOURCES.—

In making awards under clause (i), the Secretary shall encourage awardees to use science-based resources such as the Inside Knowledge About Gynecologic Cancer education campaign of the Centers for Disease Control and Prevention.

“(B) PREFERENCES IN AWARDING GRANTS OR CONTRACTS.—In making awards under subparagraph (A), the Secretary shall give preference to—

“(i) applicants with demonstrated expertise in gynecologic cancer education or treatment or in working with groups of women who are at increased risk of gynecologic cancers; and

“(ii) applicants that, in the demonstration project funded by the grant or contract, will establish linkages between physicians, nurses, other key health professionals, health profession students, hospitals, payers, and State health departments.
“(C) APPLICATION.—To seek a grant or contract under subparagraph (A), an entity shall submit an application to the Secretary in such form, in such manner, and containing such agreements, assurances, and information as the Secretary determines to be necessary to carry out this paragraph.

“(D) CERTAIN REQUIREMENTS.—In making awards under subparagraph (A), the Secretary shall—

“(i) make awards, as practicable, to not fewer than five applicants; and

“(ii) ensure that information provided through demonstration projects under this paragraph is consistent with the best available medical information.

“(E) REPORT TO CONGRESS.—Not later than 24 months after the date of the enactment of the PREVENT HPV Cancers Act of 2021, and annually thereafter, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report that—
“(i) summarizes the activities of demonstration projects under subparagraph (A); “
“(ii) evaluates the extent to which the projects were effective in increasing awareness and knowledge of risk factors and early warning signs in the populations to which the projects were directed; and “
“(iii) identifies barriers to early detection and appropriate treatment of such cancers.
“(4) AUTHORIZATION OF APPROPRIATIONS.—For the purpose of carrying out this subsection, there is authorized to be appropriated $25,000,000 for the period of fiscal years 2022 through 2026.”.